In assessing surrogate clinical trial end points: drug safety is a requisite

Journal article

Peer reviewed

Thomas J Herzog, Robert L Coleman, Bradley J Monk, Deborah K Armstrong and Ronald D Alvarez

Journal of clinical oncology, Vol.33(13), pp.1511-1512

05/01/2015

PMID: 25732164

Abstract

Angiogenesis Inhibitors - therapeutic use

Female

Humans

Ovarian Neoplasms - drug therapy

Pyrimidines - therapeutic use

Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors

Sulfonamides - therapeutic use

1 Record Views

Title: In assessing surrogate clinical trial end points: drug safety is a requisite
Creators: Thomas J Herzog - University of Cincinnati
Robert L Coleman - The University of Texas MD Anderson Cancer Center
Bradley J Monk - University of Arizona
Deborah K Armstrong - Sidney Kimmel Cancer Center
Ronald D Alvarez - University of Alabama at Birmingham
Publication Details: Journal of clinical oncology, Vol.33(13), pp.1511-1512
Identifiers: 991005969145602656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article